European Union #6009 (v.6)

Export authorisation for COVID-19 vaccines

Commission Implementing Regulation (EU) 2021/1728 (29 September
2021) extending Implementing Regulation (EU) 2021/521 making specific
arrangements to the mechanism making the exportation of certain products subject to the production of an export authorisation; Official Journal L
2021/1728, 29.09.2021
https://eurlex.europa.eu/legalcontent/EN/TXT/?uri=CELE
X%3A32021R1728
Application period: from 1.10.2021 until 31.12.2021

Administration: Competent authorities in EU Member States.
Authorisations are granted to the extent that the volume of exports is such that it does not pose a threat to the execution of Advance Purchase Agreements that the European Union has concluded with vaccine manufacturers. Authorisations are granted where exports do not pose a threat to the security of supply within the European Union. In order to determine whether the condition above is fulfilled, the competent authorities
shall assess the following factors: 1) Does the destination country restrict its own exports of vaccines or their raw materials, either by law or other means?
And 2) Are the conditions prevailing in the destination country better or worse than the EU's, in particular its epidemiological situation, its vaccination rate and its access to vaccines?
Exemptions include, inter alia:
- exports in the context of humanitarian aid;
- exports to low and middle income countries in the COVAX Advance Market Commitment (AMC) list
(https://www.gavi.org/ne
ws/media-room/92-lowmiddle-incomeeconomies-eligibleaccess-covid-19-
vaccines-gavi-covax-amc
- exports of goods purchased and/or delivered through COVAX, UNICEF and PAHO with destination to any other COVAX participating country;
- EU overseas countries and territories;
- Andorra, the Faroe Islands, San Marino, Vatican City, Büsingen, Helgoland, Livigno, Ceuta and Melilla;
- Iceland, Liechtenstein and Norway.

HS 2017